COMPREHENSIVE HIV/AIDS ANTIRETROVIRAL (ART) PRODUCT LIST

The list below has been expanded to include most antiretroviral molecules and combinations currently used in the Indian HIV market, including NACO first-line, second-line, pediatric, salvage therapy, and private-market products. Current Indian HIV treatment is heavily centered on Dolutegravir (DTG), Tenofovir (TDF/TAF), Lamivudine (3TC), Abacavir (ABC), Darunavir (DRV), Atazanavir (ATV), Ritonavir (RTV), and Raltegravir (RAL).

Leading the Future of HIV/AIDS Treatment with Advanced Antiretroviral Medicines

Abacavir Tablets 300mg Supplier PAN India
Abacavir Tablets 300mg

The global healthcare community has made remarkable progress in the management of Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) through the widespread availability of effective Antiretroviral Therapy (ART). Modern ART regimens have transformed HIV infection from a life-threatening condition into a manageable chronic disease, enabling millions of people worldwide to live longer, healthier, and more productive lives.

At Taj Pharma, we are dedicated to supporting governments, healthcare institutions, international procurement agencies, NGOs, hospitals, distributors, and pharmaceutical partners with a comprehensive portfolio of more than 45 HIV/ART products covering first-line, second-line, pediatric, and advanced treatment regimens. Our antiretroviral portfolio aligns with international treatment standards and includes a broad range of NRTIs, NNRTIs, Protease Inhibitors, Integrase Inhibitors, fixed-dose combinations, pediatric formulations, and next-generation HIV therapies.

NRTI (Nucleoside/Nucleotide Reverse Transcriptase Inhibitors)

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
AbacavirABATAJAntiretroviral (NRTI)Tablet300 mgClass III
LamivudineLAMITAJAntiretroviral (NRTI)Tablet150 mg, 300 mgClass III
LamivudineLAMITAJ SyrupAntiretroviral (NRTI)Syrup50 mg/5 mlClass III
ZidovudineZIDOTAJAntiretroviral (NRTI)Tablet300 mgClass I
ZidovudineZIDOTAJ SyrupAntiretroviral (NRTI)Syrup50 mg/5 mlClass I
Tenofovir Disoproxil FumarateTENOTAJAntiretroviral (NRTI)Tablet300 mgClass III
Tenofovir AlafenamideTAFTAJAntiretroviral (NRTI)Tablet25 mgClass II
EmtricitabineEMTRITAJAntiretroviral (NRTI)Capsule/Tablet200 mgClass I

NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors)

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
NevirapineNEVITAJAntiretroviral (NNRTI)Tablet200 mgClass II
NevirapineNEVITAJ SuspensionOral Suspension10 mg/mlClass II
EfavirenzEFAVITAJAntiretroviral (NNRTI)Tablet400 mg, 600 mgClass II
EtravirineETRATAJAntiretroviral (NNRTI)Tablet100 mg, 200 mgClass II
RilpivirineRILPITAJAntiretroviral (NNRTI)Tablet25 mgClass II
DoravirineDORATAJAntiretroviral (NNRTI)Tablet100 mgClass II

Comprehensive HIV/AIDS Treatment Solutions

The management of HIV infection requires carefully selected combinations of antiretroviral medicines that suppress viral replication, strengthen immune function, reduce opportunistic infections, and support long-term treatment success.

Our HIV portfolio has been designed to address the diverse therapeutic needs of healthcare systems worldwide, ensuring access to high-quality medicines across all stages of HIV treatment.

The Taj Pharma HIV portfolio includes:

  • Adult HIV treatment formulations
  • Pediatric HIV formulations
  • First-line ART regimens
  • Second-line ART regimens
  • Salvage therapy products
  • Fixed-dose combinations (FDCs)
  • Single-agent antiretroviral medicines
  • Advanced integrase inhibitor-based therapies
  • Modern tenofovir alafenamide-based regimens

Protease Inhibitors (PI)

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
RitonavirRITOTAJProtease Inhibitor BoosterTablet100 mgClass IV
AtazanavirATAZATAJProtease InhibitorCapsule150 mg, 300 mgClass II
Lopinavir + RitonavirLOPIRITAJProtease Inhibitor CombinationTablet200 mg + 50 mgClass IV
DarunavirDARUTAJProtease InhibitorTablet400 mg, 600 mg, 800 mgClass IV
Darunavir + RitonavirDARURITAJProtease Inhibitor CombinationTablet400/50 mg, 600/100 mg, 800/100 mgClass IV
Atazanavir + RitonavirATAZRITAJProtease Inhibitor CombinationTablet300 mg + 100 mgClass II

Integrase Strand Transfer Inhibitors (INSTI)

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
DolutegravirDOLUTAJIntegrase InhibitorTablet50 mgClass II
Dolutegravir PediatricDOLUTAJ JuniorIntegrase InhibitorTablet10 mgClass II
RaltegravirRALTEGTAJIntegrase InhibitorTablet400 mgClass II
RaltegravirRALTEGTAJ ChewChewable Tablet100 mgClass II
ElvitegravirELVITAJIntegrase InhibitorTablet150 mgClass II
BictegravirBICTAJIntegrase InhibitorTablet50 mgClass II

DUAL COMBINATIONS

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class
Lamivudine + ZidovudineLAMIZIDTAJNRTI CombinationTablet150 mg + 300 mgIII
Lamivudine + Zidovudine DTLAMIZIDTAJ DTPediatric FDCDispersible Tablet30 mg + 60 mgIII
Abacavir + LamivudineABALAMTAJNRTI CombinationTablet120/60 mg, 600/300 mgIII
Tenofovir + LamivudineTENLAMTAJNRTI CombinationTablet300 mg + 300 mgIII
Tenofovir + EmtricitabineTENEMTAJNRTI CombinationTablet300 mg + 200 mgIII
Tenofovir Alafenamide + EmtricitabineTAFEMTAJNRTI CombinationTablet25 mg + 200 mgII
Dolutegravir + LamivudineDOLLAMTAJDual TherapyTablet50 mg + 300 mgII

TRIPLE COMBINATIONS (FIRST-LINE & MODERN ART)

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class
Tenofovir + Lamivudine + Dolutegravir (TLD)TLDTAJFirst-Line ARTTablet300 + 300 + 50 mgII
Tenofovir + Emtricitabine + DolutegravirTENEMDOLTAJTriple ARTTablet300 + 200 + 50 mgII
Tenofovir Alafenamide + Emtricitabine + DolutegravirTAFEMDOLTAJAdvanced Triple ARTTablet25 + 200 + 50 mgII
Lamivudine + Tenofovir + EfavirenzLAMTENEFTAJTriple ARTTablet300 + 300 + 400 mgII
Lamivudine + Tenofovir + EfavirenzLAMTENEFTAJ ForteTriple ARTTablet300 + 300 + 600 mgII
Abacavir + Lamivudine + DolutegravirABALAMDOLTAJTriple ARTTablet600 + 300 + 50 mgIII
Abacavir + Lamivudine + Dolutegravir PediatricABALAMDOLTAJ DTPediatric Triple ARTDispersible Tablet60 + 30 + 5 mgIII
Zidovudine + Lamivudine + NevirapineZLAMNEVTAJTriple ARTTablet300 + 150 + 200 mgIII
Zidovudine + Lamivudine + EfavirenzZLAMEFTAJTriple ARTTablet300 + 150 + 600 mgIII

SECOND-LINE & SALVAGE REGIMEN PRODUCTS

Widely used in India for treatment-experienced or resistant HIV patients.

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class
Atazanavir + RitonavirATAZRITAJSecond-Line ARTTablet300 + 100 mgII
Darunavir + RitonavirDARURITAJSecond-Line ARTTablet600 + 100 mgIV
Darunavir + Ritonavir + DolutegravirDARUDOLTAJSalvage TherapyTablet Kit600 + 100 + 50 mgIV
Lopinavir/Ritonavir + DolutegravirLOPIDOLTAJSalvage TherapyTablet KitVariousIV
Tenofovir + Lamivudine + Atazanavir/RitonavirTENLAMATAJ-RSecond-Line ART KitKitVariousIII
Zidovudine + Lamivudine + Atazanavir/RitonavirZLAMATAJ-RSecond-Line ART KitKitVariousIII

NEWER PRIVATE-MARKET HIV PRODUCTS

Available primarily in private HIV care and specialty markets.

Product NameBrand NameTherapeutic CategoryDosage FormAvailable Strengths
Bictegravir + Emtricitabine + Tenofovir AlafenamideBICTEMTAFTAJSingle Tablet RegimenTablet50 + 200 + 25 mg
Dolutegravir + RilpivirineDOLRILTAJTwo Drug RegimenTablet50 + 25 mg
Doravirine + Lamivudine + TenofovirDORLAMTENTAJTriple ARTTablet100 + 300 + 300 mg


NRTI Antiretroviral Medicines: Foundation of HIV Treatment

Abacavir (ABATAJ)

Abacavir remains one of the most important nucleoside reverse transcriptase inhibitors used in HIV treatment. It is commonly utilized in both adult and pediatric antiretroviral regimens and serves as a critical component of numerous combination therapies.

Available Strengths

  • Abacavir 300 mg Tablets

Key Applications

  • First-line HIV treatment
  • Pediatric HIV regimens
  • Fixed-dose combinations
  • Alternative backbone therapy

Lamivudine (LAMITAJ)

Lamivudine is one of the most widely prescribed HIV medicines globally. Its established efficacy and excellent tolerability make it a cornerstone component of numerous antiretroviral combinations.

Available Formulations

  • Lamivudine 150 mg Tablets
  • Lamivudine 300 mg Tablets
  • Lamivudine Oral Syrup

Benefits

  • High treatment acceptance
  • Strong clinical experience
  • Broad inclusion in ART guidelines

Tenofovir Disoproxil Fumarate (TENOTAJ)

Tenofovir DF remains a critical first-line HIV medicine used in millions of treatment regimens worldwide.

Advantages

  • Potent antiviral activity
  • Once-daily dosing compatibility
  • Extensive clinical evidence
  • Preferred backbone therapy

Tenofovir Alafenamide (TAFTAJ)

Tenofovir Alafenamide represents a modern advancement in HIV treatment and has become an increasingly important component of contemporary antiretroviral therapy.

Clinical Advantages

  • Advanced formulation technology
  • Strong antiviral efficacy
  • Suitable for modern treatment protocols

Emtricitabine (EMTRITAJ)

Emtricitabine is frequently combined with tenofovir-based therapies and plays a central role in modern HIV treatment programs.

Benefits

  • Excellent compatibility with fixed-dose combinations
  • Strong antiviral profile
  • Broad global acceptance

NNRTI-Based HIV Medicines

Nevirapine (NEVITAJ)

Nevirapine has maintained an important role in HIV treatment, particularly within pediatric treatment programs and established ART protocols.

Available Formulations

  • Nevirapine 200 mg Tablets
  • Nevirapine Oral Suspension

Efavirenz (EFAVITAJ)

Efavirenz has long been recognized as one of the most widely used NNRTIs in HIV treatment history.

Available Strengths

  • 400 mg Tablets
  • 600 mg Tablets

Clinical Applications

  • First-line treatment regimens
  • Fixed-dose combinations
  • Global ART programs

Etravirine, Rilpivirine and Doravirine

Modern NNRTIs continue to expand treatment options for HIV-positive patients requiring individualized therapy.

Portfolio Coverage

  • ETRATAJ (Etravirine)
  • RILPITAJ (Rilpivirine)
  • DORATAJ (Doravirine)

These medicines provide additional flexibility for healthcare professionals managing treatment-experienced patients and specialized HIV populations.


Integrase Inhibitors: Modern Standard of HIV Care

Integrase inhibitors have become the preferred choice in many HIV treatment guidelines due to their potency, safety profile, and rapid viral suppression.

Dolutegravir (DOLUTAJ)

Dolutegravir is widely recognized as one of the most effective antiretroviral medicines available today.

Available Strengths

  • Dolutegravir 50 mg Tablets
  • Dolutegravir 10 mg Pediatric Tablets

Advantages

  • High genetic barrier to resistance
  • Rapid viral suppression
  • Once-daily treatment compatibility
  • Preferred first-line therapy component

Raltegravir (RALTEGTAJ)

Raltegravir remains a highly effective integrase inhibitor suitable for both adult and pediatric HIV treatment.

Available Formulations

  • Raltegravir 400 mg Tablets
  • Raltegravir 100 mg Chewable Tablets

Benefits

  • Proven efficacy
  • Pediatric suitability
  • Flexible treatment options

Elvitegravir and Bictegravir

The newest generation of integrase inhibitors continues to improve treatment outcomes and simplify HIV management.

Available Products

  • ELVITAJ (Elvitegravir)
  • BICTAJ (Bictegravir)

These molecules represent advanced options within modern HIV treatment strategies.


Protease Inhibitors for Second-Line and Advanced HIV Treatment

Protease inhibitors remain essential in the management of treatment-experienced patients and second-line HIV therapy.

Atazanavir (ATAZATAJ)

Atazanavir is widely utilized as part of boosted protease inhibitor regimens.

Available Strengths

  • 150 mg Capsules
  • 300 mg Capsules

Clinical Benefits

  • Strong antiviral activity
  • Proven long-term effectiveness
  • Widely used in second-line ART

Lopinavir + Ritonavir (LOPIRITAJ)

This established combination remains a trusted option in HIV treatment programs worldwide.

Available Strength

  • 200 mg + 50 mg Tablets

Darunavir (DARUTAJ) and Darunavir + Ritonavir (DARURITAJ)

Darunavir-based therapy plays a critical role in managing resistant HIV infections and treatment-experienced patients.

Available Strengths

  • Darunavir 400 mg
  • Darunavir 600 mg
  • Darunavir 800 mg
  • Darunavir/Ritonavir combinations

Benefits

  • High resistance barrier
  • Effective salvage therapy option
  • Preferred second-line regimen component

Fixed-Dose Combination HIV Medicines

Fixed-dose combinations improve adherence by reducing pill burden and simplifying treatment schedules.

TENLAMTAJ

Tenofovir + Lamivudine

A widely used dual NRTI backbone combination.


TENEMTAJ

Tenofovir + Emtricitabine

One of the most recognized HIV treatment combinations worldwide.


ABALAMTAJ

Abacavir + Lamivudine

Available in pediatric and adult strengths for broad treatment coverage.


DOLLAMTAJ

Dolutegravir + Lamivudine

A modern dual-drug therapy option supporting simplified HIV management.


Triple Antiretroviral Therapy Products

TLDTAJ

Tenofovir + Lamivudine + Dolutegravir

The preferred first-line ART regimen in many national HIV treatment programs.

Advantages

  • Simplified once-daily therapy
  • Excellent treatment outcomes
  • High patient adherence

TENEMDOLTAJ

Tenofovir + Emtricitabine + Dolutegravir

An advanced triple-drug regimen combining potent antiviral activity with treatment convenience.


TAFEMDOLTAJ

Tenofovir Alafenamide + Emtricitabine + Dolutegravir

A modern HIV treatment option designed to meet evolving clinical requirements.


LAMTENEFTAJ

Lamivudine + Tenofovir + Efavirenz

A globally established triple-combination ART regimen.


ABALAMDOLTAJ

Abacavir + Lamivudine + Dolutegravir

Available in adult and pediatric formulations, supporting comprehensive HIV treatment across age groups.


Pediatric HIV Treatment Portfolio

Children living with HIV require specialized formulations designed for accurate dosing and improved adherence.

Taj Pharma offers an extensive pediatric HIV portfolio including:

  • Nevirapine Oral Suspension
  • Lamivudine Oral Syrup
  • Zidovudine Oral Syrup
  • Dolutegravir Pediatric Tablets
  • Raltegravir Chewable Tablets
  • Lamivudine + Zidovudine Dispersible Tablets
  • Abacavir + Lamivudine + Dolutegravir Dispersible Tablets

These formulations help support treatment continuity from infancy through adolescence.


WHO and NACO-Aligned HIV Treatment Coverage

Our HIV product portfolio supports treatment strategies aligned with internationally recognized HIV management practices and national treatment programs.

Coverage includes:

  • First-line HIV treatment regimens
  • Second-line HIV treatment regimens
  • Integrase inhibitor-based therapies
  • Protease inhibitor-based regimens
  • Pediatric HIV treatment protocols
  • Treatment-experienced patient management
  • Advanced salvage therapy solutions

This comprehensive approach enables healthcare providers to manage HIV effectively across a wide range of clinical scenarios.


Global Manufacturing Excellence at Taj Pharma

Quality, safety, and reliability remain central to every HIV medicine manufactured by Taj Pharma.

Our manufacturing operations support:

  • WHO-GMP Standards
  • International Quality Systems
  • Regulatory Documentation Support
  • Government Tender Participation
  • Ministry of Health Procurement Programs
  • NGO Supply Programs
  • International HIV Treatment Initiatives
  • Global Pharmaceutical Distribution Networks

Through rigorous quality assurance and continuous innovation, we remain committed to expanding access to affordable, high-quality HIV medicines worldwide.

With more than 45 HIV/ART products, Taj Pharma offers one of the most comprehensive antiretroviral portfolios available for global healthcare markets. Covering NRTIs, NNRTIs, Protease Inhibitors, Integrase Inhibitors, pediatric formulations, fixed-dose combinations, first-line regimens, second-line therapies, and advanced HIV treatment solutions, our portfolio supports the evolving needs of healthcare providers, procurement agencies, and HIV treatment programs across the world. Through quality-driven manufacturing and a commitment to global health, we continue to strengthen access to life-saving antiretroviral therapy for patients living with HIV/AIDS.